HCAT
Undervalued by 182.5% based on the discounted cash flow analysis.
Market cap | $250.56 Million |
---|---|
Enterprise Value | $240.11 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-1.15 |
Beta | 1.53 |
Outstanding Shares | 68,552,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -3.4 |
---|---|
PEG | -22.16 |
Price to Sales | 0.94 |
Price to Book Ratio | 0.75 |
Enterprise Value to Revenue | 0.77 |
Enterprise Value to EBIT | -3.44 |
Enterprise Value to Net Income | -4 |
Total Debt to Enterprise | 1.38 |
Debt to Equity | 0.88 |
No data
No data